Skip to main content

Peer Review reports

From: Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Original Submission
6 Mar 2018 Submitted Original manuscript
10 Nov 2018 Reviewed Reviewer Report - Jochen Raimann
Resubmission - Version 2
Submitted Manuscript version 2
14 Nov 2018 Editorially accepted
16 Jan 2019 Article published 10.1186/s13063-018-3053-1

You can find further information about peer review here.

Back to article page